{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"59.0","upperLimit":"70.6","value":"65.0"},{"groupId":"OG001","lowerLimit":"53.1","upperLimit":"65.1","value":"59.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"274"},{"groupId":"OG001","value":"272"}],"units":"Participants"}],"description":"Clinical benefit rate is defined as the percentage of participants who achieved a confirmed complete response, partial response, or durable stable disease assessed by the Investigator per RECIST v1.1.\n\nCR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \\< 10 mm.\n\nPR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits.\n\nDurable SD: Stable disease for ≥ 24 weeks.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 200 mg of tislelizumab intravenously with investigator's choice of chemotherapy once every 3 weeks for up to six treatment cycles. Thereafter, participants continued treatment with 200 mg tislelizumab, with optional maintenance capecitabine (only permitted for participants who initially received capecitabine and oxaliplatin) once every 3 weeks until disease progression or unacceptable toxicity.","id":"OG000","title":"Tislelizumab + Chemotherapy"},{"description":"Participants received placebo intravenously with investigator's choice of chemotherapy once every 3 weeks for up to six treatment cycles. Thereafter, participants continued treatment with placebo with optional maintenance capecitabine (only permitted for participants who initially received capecitabine and oxaliplatin) once every 3 weeks until disease progression or unacceptable toxicity.","id":"OG001","title":"Placebo + Chemotherapy"}],"paramType":"NUMBER","populationDescription":"PD-L1 Positive Analysis Set","reportingStatus":"POSTED","timeFrame":"Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.","title":"Clinical Benefit Rate (CBR) in PD-L1 Positive Participants","type":"SECONDARY","unitOfMeasure":"percentage of participants"}